EGFR (G719S)

EGFR · Variant type: point · HGVS: p.G719S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Afatinib	100.0%	0.0%	98.50
2	Canertinib	99.9%	0.1%	96.49
3	Erlotinib	99.5%	0.5%	99.75
4	Dacomitinib	99.3%	0.7%	97.99
5	Mobocertinib	99.3%	0.7%	97.22
6	Neratinib	99.3%	0.7%	93.18
7	Osimertinib	99.2%	0.8%	97.24
8	Lazertinib	98.9%	1.1%	97.47
9	Vandetanib	98.6%	1.4%	95.74
10	Gefitinib	98.6%	1.4%	99.25
11	Lapatinib	96.6%	3.4%	99.25
12	Bosutinib	95.8%	4.2%	87.22
13	Ibrutinib	92.1%	7.9%	94.74
14	Defactinib	90.6%	9.4%	92.68
15	Dasatinib	83.5%	16.5%	87.97
16	Zanubrutinib	73.1%	26.9%	98.24
17	Pralsetinib	73.0%	27.0%	93.43
18	Ponatinib	62.4%	37.6%	78.23
19	Fostamatinib	52.8%	47.2%	96.74
20	Capmatinib	43.7%	56.3%	99.75
21	Brigatinib	42.9%	57.1%	82.96
22	Pacritinib	41.9%	58.1%	88.64
23	Alectinib	28.5%	71.5%	95.49
24	Imatinib	28.3%	71.7%	99.00
25	Gilteritinib	27.5%	72.5%	88.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Afatinib	100.0%	100.0%	+0.0%
Canertinib	99.9%	98.4%	+1.4%
Erlotinib	99.5%	99.4%	+0.0%
Dacomitinib	99.3%	99.8%	-0.5%
Mobocertinib	99.3%	100.0%	-0.7%
Neratinib	99.3%	100.0%	-0.7%
Osimertinib	99.2%	99.1%	+0.1%
Lazertinib	98.9%	100.0%	-1.1%
Vandetanib	98.6%	99.3%	-0.7%
Gefitinib	98.6%	99.9%	-1.3%
Lapatinib	96.6%	99.2%	-2.5%
Bosutinib	95.8%	99.3%	-3.5%
Ibrutinib	92.1%	99.3%	-7.3%
Defactinib	90.6%	94.6%	-4.0%
Dasatinib	83.5%	97.9%	-14.4%
Zanubrutinib	73.1%	88.2%	-15.1%
Pralsetinib	73.0%	99.1%	-26.2%
Ponatinib	62.4%	—	—
Fostamatinib	52.8%	97.8%	-45.0%
Capmatinib	43.7%	—	—
Brigatinib	42.9%	98.5%	-55.6%
Pacritinib	41.9%	—	—
Alectinib	28.5%	—	—
Imatinib	28.3%	—	—
Gilteritinib	27.5%	91.0%	-63.5%

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 26.2ms